INTH 454
Alternative Names: INTH-454Latest Information Update: 28 Nov 2023
At a glance
- Originator Inthera Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (PO)
- 22 Jun 2020 Pharmacodynamics data from preclinical studies in Solid tumors presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)
- 26 Oct 2019 Pharmacodynamics data from preclinical studies in solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 (AACR-NCI-EORTC-2019)